Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 23 Squamous Cell Carcinoma of Head and Neck 10 Melanoma 8 Lung Neoplasms 8 Neoplasms 7 Carcinoma 6 Skin Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Squamous Cell 5 Carcinoma, Basal Cell 5 Adenocarcinoma 5 Mouth Neoplasms 4 Head and Neck Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Oropharyngeal Neoplasms 3 Laryngeal Neoplasms 3 Carcinoma, Merkel Cell 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Mesothelioma, Malignant 2 Hemangiosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Adrenocortical Carcinoma 2

Interventions

pembrolizumab 6 Cisplatin 5 Radiotherapy 4 Paclitaxel 3 Nivolumab 3 lenvatinib 2 Specimen Handling 2 Platinum 2 Papillomavirus Vaccines 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Gemcitabine 2 Carboplatin 2 CTLA-4 Antigen 2 Bleomycin 2 Bevacizumab 2 1,2-diaminocyclohexaneplatinum II citrate 2 zimberelimab 1 rocakinogene sifuplasmid 1 liposomal doxorubicin 1 durvalumab 1 dostarlimab 1 cemiplimab 1 belzutifan 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alovudine 1 aldesleukin 1 Watchful Waiting 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Vulvar Neoplasms × cemiplimab × Clear all

NCT07101848 2025-08-03

BRAVA VULVAR

Hospital Israelita Albert Einstein

Phase 2 Not yet recruiting

Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡